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Clinical PerspectiveWhat Is New?We analyzed \>33 000 real‐world aortic valve replacements and identified subgroups which benefit from transfemoral transcatheter aortic valve replacement.In all subgroups, patients undergoing transfemoral transcatheter aortic valve replacement had lower adjusted risk for acute kidney injuries, lower risk of bleeding, and lower risk for prolonged mechanical ventilation compared with patients undergoing surgical aortic valve replacement**.**The risk for in‐hospital mortality was lower in patients at increased operative risk, aged \>80 years, in patients with advanced kidney failure, and in highly symptomatic patients.What are the Clinical Implications?Results from randomized controlled trials are transferable into clinical practice.Transfemoral transcatheter aortic valve replacement should be preferentially considered in patients at increased operative risk, aged \>80 years, with advanced kidney failure, and highly symptomatic.

Introduction {#jah33954-sec-0008}
============

The first transcatheter aortic valve replacement (TAVR) was performed in 2002 in a patient with severe aortic stenosis suffering from cardiogenic shock unsuited for surgical aortic valve replacement (SAVR) because of a critical perioperative state.[1](#jah33954-bib-0001){ref-type="ref"} During the following years, TAVR became an alternative for inoperable patients suffering from aortic valve stenosis. After 5 years of development and trials, 2 valves received the European certification for application in humans. These valves showed non‐inferiority to SAVR in 2 randomized controlled trials with patients at extreme or high operative risk.[2](#jah33954-bib-0002){ref-type="ref"}, [3](#jah33954-bib-0003){ref-type="ref"} Consequently, guidelines adopted TAVR as a treatment option for patients with severe aortic valve stenosis at high operative risk.[4](#jah33954-bib-0004){ref-type="ref"} TAVR procedures soon outnumbered SAVR in clinical practice.[5](#jah33954-bib-0005){ref-type="ref"} Advances in transcatheter technology and learning effects over time further improved results after TAVR.[6](#jah33954-bib-0006){ref-type="ref"} Several large registries proved that the convincing results from randomized controlled trials are transferable into clinical practice.[7](#jah33954-bib-0007){ref-type="ref"}, [8](#jah33954-bib-0008){ref-type="ref"}, [9](#jah33954-bib-0009){ref-type="ref"} Subsequently, 2 randomized controlled trials compared TAVR and SAVR in patients at intermediate operative risk and demonstrated non‐inferiority of TAVR after 2 years of follow‐up.[10](#jah33954-bib-0010){ref-type="ref"}, [11](#jah33954-bib-0011){ref-type="ref"} Transfemoral TAVR (TF‐TAVR) with a balloon‐expandable valve was even superior to SAVR in a propensity‐matched analysis.[12](#jah33954-bib-0012){ref-type="ref"} These results led to a further modification of the guidelines: TAVR is now recommended for patients at intermediate or high operative risk.[13](#jah33954-bib-0013){ref-type="ref"} Nevertheless, risk scores are not the only criteria for the decision between SAVR and TAVR: SAVR remains the preferred method for patients aged \<75 years, since there are concerns about the durability of transcatheter valves. On the other hand, TAVR is recommended in case of severe comorbidities which are not adequately reflected by risk scores.[13](#jah33954-bib-0013){ref-type="ref"} Data from randomized controlled trials or large registries comparing both treatment strategies in younger patients or in patients with distinct comorbidities are still lacking. This may be because of limited cohort sizes in studies and resulting difficulties in obtaining statistically significant results for subgroups. However, breaking down the outcomes achieved by patients treated with the various approaches by patient subgroup is vital to provide an empirical basis for clinical practice, which is faced with a highly diverse patient population. For an accurate estimation of treatment effects within subgroups, estimates from observational databases can complement randomized controlled trials.[14](#jah33954-bib-0014){ref-type="ref"} This is particularly true for subgroups for which randomized controlled trials are not feasible because of financial constraints.

The aim of the present study is to perform subgroup analyses for a variety of at‐risk populations with sufficient patient numbers to achieve conclusive results. To this end, we analyzed the records of 33 789 SAVR or TF‐TAVR procedures performed in Germany between 2014 and 2015 on the basis of *International Classification of Diseases (ICD)* and OPS (Operation and procedure key) codes.

Methods {#jah33954-sec-0009}
=======

Data Acquisition {#jah33954-sec-0010}
----------------

Since 2005, data on all hospitalizations in Germany have been available for scientific use via the Diagnosis Related Groups statistics collected by the Research Data Center of the Federal Bureau of Statistics (DESTATIS). These hospitalization data, including diagnoses and procedures, are a valuable source of representative nationwide data on the in‐hospital treatment of patients. This database represents a virtually complete collection of all hospitalizations in German hospitals that are reimbursed according to the Diagnosis Related Groups system. From this database, we extracted data on 33 789 cases of isolated SAVR and TF‐TAVR procedures conducted in 2014 or 2015. As described previously, patients with a baseline diagnosis of pure aortic regurgitation (main or secondary diagnosis other than I35.0, I35.2, I06.0, I06.2) and those with concomitant cardiac surgery or percutaneous coronary intervention were not included in this analysis.[5](#jah33954-bib-0005){ref-type="ref"} A complete list of procedure codes as well as a more detailed discussion of the validity of the data source may be found in Table [S1](#jah33954-sup-0001){ref-type="supplementary-material"}.

Our study did not involve direct access by the investigators to data on individual patients but only access to summary results provided by the Research Data Center. Therefore, approval by an ethics committee and informed consent were determined not to be required, in accordance with German law. All summary results were anonymized by DESTATIS. In practice, this means that any information allowing the drawing of conclusions about a single patient or a specific hospital was censored by DESTATIS to guarantee data protection. Moreover in order to prevent the possibility to draw conclusions to a single hospital, the data are verified and situationally censored by DESTATIS in those cases.

Definition of End Points {#jah33954-sec-0011}
------------------------

The analysis focuses on 7 different end points: in‐hospital mortality, stroke, acute kidney injury, bleeding events, ventilator therapy of \>48 hours, permanent pacemaker implantation, and length of hospital stay. Stroke and acute kidney injury were defined using *ICD, Tenth Revision (ICD‐10)* codes (secondary diagnosis I63\* or I64 and N17\*, respectively). Bleeding was defined as requiring a transfusion of \<5 units of red blood cells and defined using OPS‐codes (8‐800.c1 to 8‐800.cr), as was the case for permanent pacemaker implantation (5‐377.0 to 5‐377.7). In‐hospital mortality, length of mechanical ventilation, and length of hospital stay were part of DESTATIS' main set of variables. For all other comorbidities, the existing anamnestic or acute distinctive codes were used (we have discussed OPS and *ICD* codes in detail previously[5](#jah33954-bib-0005){ref-type="ref"}). For calculation of the estimated logistic EuroSCORE (European System for Cardiac Operative Risk Evaluation), we were able to populate all fields except for critical preoperative state and left ventricular function. In these, we assumed an inconspicuous state (i.e, no critical preoperative state and no left ventricular dysfunction) and thus calculated a best‐case scenario. To allow a direct comparison of the baseline risk factor composition between TAVR and SAVR patients, we calculated logistic EuroSCORE values assuming isolated SAVR procedures for both groups.

Statistical Analysis {#jah33954-sec-0012}
--------------------

The primary outcome was in‐hospital mortality. Secondary outcomes include post‐procedural complications such as stroke and bleeding events (transfusion of ≥5 red blood cells), as well as the proportion of patients with ventilator therapy \>48 hours and permanent pacemaker implantation.

In a previous study, Reinohl et al[5](#jah33954-bib-0005){ref-type="ref"} identified 20 baseline patient characteristics to describe risk profiles between procedural groups. Since patients were not randomized to the 2 treatment options (TF‐TAVR or SAVR), logistic or linear regression models were used with these 20 baseline patient characteristics included as potential confounders (all covariates listed in Table [1](#jah33954-tbl-0001){ref-type="table"}). Year 2015 was added as an additional confounder to improve the precision of the estimates. To account for the correlation of error terms of patients treated in the same hospital, a random intercept was included at the center level.

###### 

Baseline Characteristics in SAVR and TF‐TAVR Performed in 2014 and 2015. *p*‐Values are calculated using the students *t*‐test (age, EuroSCORE) or chi‐square test

                                     SAVR (n=13 151)   TF‐TAVR (n=20 638)   *P* Value            
  ---------------------------------- ----------------- -------------------- ----------- -------- ---------
  Logistic EuroSCORE, mean/SD        5.30              4.66                 13.91       10.29    \<0.001
  Age in y, mean/SD                  68.53             10.04                81.12       6.03     \<0.001
  Women, n %                         5057              38.45%               11 251      54.52%   \<0.001
  NYHA II, n %                       1745              13.27%               2020        9.79%    \<0.001
  NYHA III or IV, n %                3746              28.48%               9572        46.38%   \<0.001
  CAD, n %                           2525              19.20%               9760        47.29%   \<0.001
  Hypertension, n %                  8091              61.52%               13 029      63.13%   0.003
  Previous MI within 4 mo, n %       68                0.52%                297         1.44%    \<0.001
  Previous MI within 1 y, n %        38                0.29%                135         0.65%    \<0.001
  Previous MI after 1 y, n %         256               1.95%                804         3.90%    \<0.001
  Previous CABG, n %                 248               1.89%                1895        9.18%    \<0.001
  Previous cardiac surgery, n %      656               4.99%                2960        14.34%   \<0.001
  Peripheral vascular disease, n %   598               4.55%                1835        8.89%    \<0.001
  Carotid disease, n %               478               3.63%                1032        5.00%    \<0.001
  COPD, n %                          1189              9.04%                2711        13.14%   \<0.001
  Pulmonary hypertension             1330              10.11%               4286        20.77%   \<0.001
  Renal disease, GFR \<15, n %       117               0.89%                460         2.23%    \<0.001
  Renal disease, GFR \<30, n %       171               1.30%                911         4.41%    \<0.001
  Atrial fibrillation, n %           5246              39.89%               9266        44.90%   \<0.001
  Diabetes mellitus, n %             3311              25.18%               6735        32.63%   \<0.001

CABG indicates coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; EuroSCORE, European System for Cardiac Operative Risk Evaluation; GFR, glomerular filtration rate; MI, myocardial infarction; NYHA, New York Heart Association; SAVR, surgical aortic valve replacement; TF‐TAVR, transfemoral transcatheter aortic valve replacement.

To identify subgroups of patients in which 1 of the 2 treatment options (TF‐TAVR or SAVR) might be preferable with respect to a specific outcome, a number of subgroups of interest were predefined: age groups, preoperative risk assessed by the EuroSCORE, female sex, heart failure (New York Heart Association \[NYHA\] III or IV), previous coronary artery bypass graft (CABG), peripheral vascular disease, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, renal failure (glomerular filtration rate \<30), and diabetes mellitus.

If the respective outcome rarely occurs within these subgroups there may not be enough data with which to model the relationship between the outcome and all potential confounders.[15](#jah33954-bib-0015){ref-type="ref"} Therefore, an additional propensity approach was applied within the different subgroups. First, a logistic regression model was performed on the same patient and procedural characteristics to calculate the propensity score for each patient within the different subgroups. The propensity score represents the likelihood that the patient was in the TF‐TAVR arm. Please note that the outcome variables were not used in this step. Then, propensity score adjustment was applied using the propensity score as continuous covariate.[16](#jah33954-bib-0016){ref-type="ref"} Again, logistic regression models with a random intercept at the center level were conducted.

As a result, each outcome was analyzed twice for each subgroup: once using covariate adjustment and once using propensity score adjustment. However, analyses using regression adjustment are shown as base case analyses. In the light of an ongoing discussion that covariate adjustment models might be overfitted when the number of covariates is large compared with the number of patients or outcome events, results of analyses using propensity score adjustment are compared with those from covariate adjustment when there were few events per confounder in the respective subgroup and outcome. See Figure [S1](#jah33954-sup-0001){ref-type="supplementary-material"} and Tables [S2](#jah33954-sup-0001){ref-type="supplementary-material"} through [S17](#jah33954-sup-0001){ref-type="supplementary-material"} for results of the different regression analyses.

All analyses were performed by using Stata 14 (StataCorp, College Station, Texas, USA).

Results {#jah33954-sec-0013}
=======

Patients {#jah33954-sec-0014}
--------

Between January 2014 and December 2015, 13 151 isolated SAVR and 20 638 TF‐TAVR procedures were performed in 102 different centers in Germany.

Patients undergoing TF‐TAVR were more likely to be women (female sex SAVR: 38.5%; TF‐TAVR 54.5%), were older (SAVR: 68.5 years; TF‐TAVR 81.1 years), and had more comorbidities: They suffered significantly more frequently from coronary artery disease, atrial fibrillation, carotid disease, COPD, pulmonary hypertension, renal disease, and diabetes mellitus. Furthermore, patients undergoing TF‐TAVR had more symptoms from aortic stenosis, 46% being in NYHA Class III or IV compared with 28% of patients treated with SAVR. The share of patients with previous cardiac surgery was higher in patients undergoing TF‐TAVR (SAVR: 5.0%; TF‐TAVR 14.3%). Consequently, the estimated operative risk was substantially higher in patients treated with TF‐TAVR (EuroSCORE SAVR: 5.3±4.7%; *P*\<0.001; TF‐ TAVR: 13.9±10.3%, Table [1](#jah33954-tbl-0001){ref-type="table"}).

Unadjusted In‐Hospital Outcomes {#jah33954-sec-0015}
-------------------------------

Unadjusted outcomes differed between patients treated with SAVR and TF‐TAVR. In comparison with previous years, in‐hospital mortality is low, with 2.0% after SAVR and 3.2% after TF‐TAVR, respectively (*P*\<0.001).[5](#jah33954-bib-0005){ref-type="ref"} Besides the lower mortality rate, SAVR was also associated with fewer strokes (SAVR: 1.6%; TF‐TAVR: 2.4%, *P*\<0.001), acute kidney injuries (SAVR: 4.8%; TF‐ TAVR: 5.5%, *P*=0.006), and pacemaker implantations (SAVR: 4.0%; TF‐ TAVR: 16.9%, *P*\<0.001). On the other hand, bleeding (\>5 units of red blood cells, SAVR: 9.5%; TF‐ TAVR: 3.3%, *P*\<0.001), and prolonged mechanical ventilation rates (\>48 hours, SAVR: 7.0%;TF‐ TAVR: 2.9%, *P*\<0.001) were higher among SAVR patients (Table [2](#jah33954-tbl-0002){ref-type="table"}). Unadjusted length of hospital stay was comparable for SAVR and TF‐TAVR patients (14.7 and 14.9 days, *P*=0.123).

###### 

In‐Hospital Outcomes in SAVR and TF‐TAVR Performed in 2014 and 2015

                                     SAVR    TF‐TAVR   Unadjusted Comparison            
  ---------------------------------- ------- --------- ----------------------- -------- ---------
  In‐hospital mortality              262     1.99%     667                     3.23%    \<0.001
  Stroke                             213     1.62%     500                     2.42%    \<0.001
  Acute kidney injury                637     4.84%     1144                    5.54%    0.006
  Bleeding \>5 units                 1245    9.47%     673                     3.26%    \<0.001
  Mechanical ventilation \>48 h      921     7.00%     607                     2.94%    \<0.001
  New permanent pacemaker            527     4.01%     3492                    16.92%   \<0.001
  Length of hospital stay, mean SD   14.73   9.55      14.90                   9.66     0.123

*P* values are calculated using the Chi‐square test or the students *t* test (length of hospital stay). SAVR indicates surgical aortic valve replacement; TF‐TAVR, transfemoral transcatheter aortic valve replacement.

Risk‐Adjusted Outcomes {#jah33954-sec-0016}
----------------------

After risk adjustment, the effect of treatment selection on in‐hospital outcomes was slightly different: In‐hospital mortality and stroke were similar (TF‐TAVR compared with SAVR mortality: OR 0.83, *P*=0.068, stroke OR 1.07, *P*=0.558) in the entire population. However, TF‐TAVR was associated with a lower risk for acute kidney injuries (OR 0.62, *P*\<0.001), for bleeding (OR 0.17, *P*\<0.001), and for prolonged ventilation (OR 0.21, *P*\<0.001). As expected, patients undergoing TF‐TAVR had an increased risk for pacemaker implantations even after risk adjustment (OR 4.61, *P*\<0.001, Figure [1](#jah33954-fig-0001){ref-type="fig"}). In addition, TF‐TAVR was associated with a shorter length of hospital stay (−1.33 days, *P*\<0.001).

![Risk‐adjusted in‐hospital outcomes in SAVR and TF‐TAVR performed in 2014 and 2015. Results of multivariate logistic regression analyses with 20 predefined baseline patient characteristics included as potential confounders (all covariates listed in Table [1](#jah33954-tbl-0001){ref-type="table"}). SAVR indicates surgical aortic valve replacement; TF‐TAVR, transfemoral transcatheter aortic valve replacement.](JAH3-8-e011504-g001){#jah33954-fig-0001}

Risk‐Adjusted Mortality in Different Subgroups {#jah33954-sec-0017}
----------------------------------------------

Although guidelines in 2014 and 2015 recommended TAVR for patients at high operative risk, a remarkable share of patients undergoing TF‐TAVR were \<75 years or at intermediate or low operative risk in clinical practice. The outcomes of SAVR and TF‐TAVR differed in those subgroups (Table [3](#jah33954-tbl-0003){ref-type="table"}). To identify subgroups of patients who benefited from either SAVR or TF‐TAVR, we analyzed outcomes in different pre‐defined subgroups.

###### 

In‐Hospital Outcomes in Different Subgroups

                                              n        Age, Mean (y)   EuroSCORE, Mean   In‐Hospital Mortality, %   Stroke, %   Acute Kidney Injury, %   Bleeding \>5 Units, %   Mechanical Ventilation \>48 H, %   New Permanent Pacemaker, %   Length of Hospital Stay, Mean D
  ------------------------------------------- -------- --------------- ----------------- -------------------------- ----------- ------------------------ ----------------------- ---------------------------------- ---------------------------- ---------------------------------
  Patients aged \<75 y                                                                                                                                                                                                                           
  SAVR                                        8793     63.7            3.8               1.5%                       1.4%        4.0%                     7.8%                    6.1%                               4.0%                         14.3
  TF‐TAVR                                     2280     69.7            8.3               2.5%                       2.0%        6.1%                     4.1%                    4.4%                               15.8%                        15.3
  Patients aged 75 to 79 y                                                                                                                                                                                                                       
  SAVR                                        3225     76.9            7.5               2.4%                       2.1%        5.6%                     11.5%                   8.4%                               3.9%                         15.3
  TF‐TAVR                                     5067     77.3            11.0              2.5%                       2.1%        5.5%                     2.9%                    2.8%                               16.1%                        14.7
  Patients aged 80 to 84 y                                                                                                                                                                                                                       
  SAVR                                        980      81.5            9.8               4.1%                       1.6%        8.7%                     15.4%                   8.7%                               4.5%                         15.9
  TF‐TAVR                                     7303     82.0            13.7              3.1%                       2.6%        5.0%                     3.3%                    2.8%                               17.1%                        14.6
  Patients aged ≥85 y                                                                                                                                                                                                                            
  SAVR                                        153      86.2            14.6              8.5%                       XXX         12.4%                    22.9%                   16.3%                              5.2%                         18.4
  TF‐TAVR                                     5988     87.6            18.8              4.2%                       XXX         6.0%                     3.2%                    2.6%                               17.8%                        15.4
  Patients with EuroSCORE \<4                                                                                                                                                                                                                    
  SAVR                                        6325     61.8            2.4               0.9%                       0.7%        2.8%                     5.6%                    4.3%                               3.7%                         13.1
  TF‐TAVR                                     748      68.3            3.1               1.7%                       0.5%        3.3%                     2.0%                    2.8%                               15.2%                        12.7
  Patients with EuroSCORE 4 to 9                                                                                                                                                                                                                 
  SAVR                                        5056     74.2            5.8               2.3%                       1.7%        5.3%                     10.3%                   7.3%                               3.8%                         15.2
  TF‐TAVR                                     7258     79.1            6.6               2.1%                       1.3%        3.6%                     2.3%                    2.2%                               15.3%                        13.1
  Patients with EuroSCORE \>9                                                                                                                                                                                                                    
  SAVR                                        1770     76.4            14.4              5.1%                       4.6%        10.8%                    20.7%                   15.8%                              5.6%                         19.4
  TF‐TAVR                                     12 632   83.0            18.8              4.0%                       3.2%        6.8%                     3.9%                    3.3%                               17.9%                        16.1
  Patients with female sex                                                                                                                                                                                                                       
  SAVR                                        5057     70.3            6.4               1.8%                       1.5%        4.4%                     10.4%                   6.5%                               3.8%                         14.9
  TF‐TAVR                                     11 251   81.9            15.2              3.3%                       2.5%        5.0%                     3.6%                    2.4%                               16.4%                        15.3
  Patients with heart failure (NYHA III/IV)                                                                                                                                                                                                      
  SAVR                                        3746     69.6            6.4               3.9%                       1.8%        9.0%                     12.7%                   10.5%                              4.5%                         16.5
  TF‐TAVR                                     9572     81.2            15.4              4.3%                       2.6%        8.1%                     4.1%                    4.2%                               17.8%                        16.4
  Patients with previous CABG                                                                                                                                                                                                                    
  SAVR                                        248      69.7            12.4              2.8%                       5.2%        6.9%                     22.2%                   13.7%                              6.9%                         18.0
  TF‐TAVR                                     1895     79.3            23.5              3.2%                       2.3%        7.0%                     3.4%                    3.0%                               16.8%                        14.9
  Patients with peripheral vascular disease                                                                                                                                                                                                      
  SAVR                                        598      71.3            11.1              3.2%                       2.3%        9.7%                     14.2%                   10.9%                              4.0%                         17.6
  TF‐TAVR                                     1835     80.7            23.5              4.1%                       3.7%        8.4%                     5.9%                    4.9%                               17.4%                        16.8
  Patients with COPD                                                                                                                                                                                                                             
  SAVR                                        1189     69.6            8.8               3.5%                       1.6%        7.7%                     13.8%                   13.0%                              4.0%                         17.2
  TF‐TAVR                                     2711     80.1            19.2              4.2%                       2.2%        8.0%                     3.8%                    4.7%                               16.5%                        16.5
  Patients with pulmonary hypertension                                                                                                                                                                                                           
  SAVR                                        1330     69.9            11.1              4.2%                       2.0%        9.5%                     15.2%                   13.8%                              5.2%                         17.8
  TF‐TAVR                                     4286     81.3            23.1              4.6%                       2.8%        7.9%                     4.0%                    3.7%                               19.3%                        17.0
  Patients with renal failure (GFR \<30)                                                                                                                                                                                                         
  SAVR                                        285      69.2            11.6              9.8%                       4.2%        17.2%                    38.9%                   25.3%                              6.7%                         24.0
  TF‐TAVR                                     1362     80.3            23.7              7.0%                       2.7%        12.6%                    7.9%                    6.2%                               19.1%                        19.1
  Patients with diabetes mellitus                                                                                                                                                                                                                
  SAVR                                        3311     70.3            6.0               2.5%                       2.1%        7.5%                     11.3%                   10.1%                              3.9%                         16.0
  TF‐TAVR                                     6735     80.0            14.2              3.1%                       2.6%        6.7%                     3.4%                    3.5%                               17.7%                        15.7

CABG indicates coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; EuroSCORE, European System for Cardiac Operative Risk Evaluation; GFR, glomerular filtration rate; NYHA, New York Heart Association; SAVR, surgical aortic valve replacement; TF‐TAVR, transfemoral transcatheter aortic valve replacement.

XXX: the value is not available anonymization concerns by the federal bureau of statistics.

Risk for mortality differed between the subgroups: among the younger patients with an age \<75 years, SAVR was the most common treatment strategy. The mortality was 1.5% after SAVR and 2.5% after TF‐TAVR, but was not significantly different after risk adjustment (OR 0.85, *P*=0.404). The same is true for the group of patients aged 75 to 79 years, where TF‐TAVR procedures outnumbered SAVR, but effect of treatment selection on in‐hospital mortality was again not significant (OR 0.82, *P*=0.219). In patients \>80 years, TF‐TAVR was the preferential treatment strategy. In these older patients, TF‐TAVR was associated with a significantly lower risk for in‐hospital mortality (aged 80--84 years: OR 0.55, *P*=0.002; aged ≥85 years: OR 0.42, *P*=0.006).

Risk scores such as the EuroSCORE are important decision criteria for SAVR or TF‐TAVR. Among patients with low operative risk (EuroSCORE values \<4), SAVR was the predominant treatment strategy, but risk‐adjusted mortality did not differ significantly (OR 1.44, *P*=0.308). Patients at intermediate (EuroSCORE values ≥4 and ≤9) and high (EuroSCORE values \>9) operative risk more frequently underwent TF‐TAVR than SAVR. Whereas adjusted mortality in patients with intermediate risk was not significantly different (OR 0.81, *P*=0.156), patients at high operative risk benefit significantly from TF‐TAVR (OR 0.62, *P*=0.006). Two further subgroups showed decreased risk for in‐hospital mortality after TF‐AVR compared with SAVR: symptomatic patients undergoing TF‐TAVR in NYHA‐Class III or IV had an odds ratio of 0.72 (*P*=0.015) for in‐hospital death. Moreover, patients with advanced renal failure benefited from TF‐TAVR after risk adjustment (OR 0.45, *P*=0.005). TF‐TAVR was the most common treatment strategy in female patients and in patients suffering from peripheral artery disease, COPD, previous coronary artery bypass graft (CABG), pulmonary hypertension, and diabetes mellitus. In those subgroups, none of the treatment strategies showed significant advantages on in‐hospital mortality (Figure [2](#jah33954-fig-0002){ref-type="fig"}).

![Subgroup‐specific treatment effects on in‐hospital mortality. Results of multivariate logistic regression analyses with 20 predefined baseline patient characteristics included as potential confounders (all covariates listed in Table [1](#jah33954-tbl-0001){ref-type="table"}). CABG indicates coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; EuroSCORE, European System for Cardiac Operative Risk Evaluation; GFR, glomerular filtration rate; NYHA, New York Heart Association.](JAH3-8-e011504-g002){#jah33954-fig-0002}

Risk‐Adjusted Complications in Different Subgroups {#jah33954-sec-0018}
--------------------------------------------------

The treatment‐related risk for in‐hospital complications varied between the different subgroups and complications: The risk for stroke was not significantly different after risk‐adjustment apart from patients with previous CABG, where the risk of stroke was smaller in patients undergoing TF‐TAVR. The odds ratio for bleeding and prolonged ventilation was lower in patients undergoing TF‐TAVR, the odds ratio for permanent pacemaker higher (Figure [S1](#jah33954-sup-0001){ref-type="supplementary-material"}). In addition, TF‐TAVR was associated with a shorter length of hospital stay than SAVR in all subgroups observed with most pronounced differences among patients aged ≥85 (−2.83 days, *P*\<0.001), at high operative risk (−2.34 days, *P*\<0.001), with previous CABG (−4.28 days, *P*\<0.001), or with renal failure (−5.40 days, *P*\<0.001, Figure [S2](#jah33954-sup-0001){ref-type="supplementary-material"}).

Discussion {#jah33954-sec-0019}
==========

In this retrospective nationwide analysis of all patients treated with isolated surgical or transcatheter aortic valve replacement in 2014 and 2015 we found reduced in‐hospital mortality after TF‐TAVR in patients at high operative risk, aged \>80 years, with advanced renal failure, and in patients suffering from severe dyspnea.

Over the analyzed time, TF‐TAVR outnumbered SAVR procedures. In accordance with current guidelines, patients undergoing TF‐TAVR had more co‐morbidities and consequently an increased operative risk. This underlines that TF‐TAVR evolved into the main treatment strategy for inoperable patients with severe aortic valve stenosis in clinical practice. Despite the advanced age and increased operative risk of patients undergoing TF‐TAVR, the outcomes are comparable between both treatment strategies: in‐hospital mortality, stroke rates, and permanent pacemaker implantations were higher, whereas need for transfusion of \>5 red blood cell units or prolonged ventilation was lower after TF‐TAVR. After adjustment for risk, the advantage of SAVR about in‐hospital stroke and mortality disappeared, and risk for bleeding, prolonged ventilation, and acute kidney failure was higher after SAVR. This confirms that results after TF‐TAVR further improved even in real‐world clinical practice because of technical improvements and learning curves.[6](#jah33954-bib-0006){ref-type="ref"} Therefore, TF‐TAVR is now a reasonable alternative to the established SAVR.[17](#jah33954-bib-0017){ref-type="ref"} Nevertheless, different pathologies in younger patients, the need for permanent pacemaker implantations, and uncertain durability raises concerns over the increase of TF‐TAVR indications, although intermediate‐term data have not revealed differences between SAVR and TAVR.[18](#jah33954-bib-0018){ref-type="ref"}, [19](#jah33954-bib-0019){ref-type="ref"}, [20](#jah33954-bib-0020){ref-type="ref"}, [21](#jah33954-bib-0021){ref-type="ref"} It is therefore crucial to identify the patient subgroups which benefit most from SAVR or TF‐TAVR. Several studies have compared the outcomes after SAVR and TAVR, but subgroup analyses are rare.[9](#jah33954-bib-0009){ref-type="ref"}, [22](#jah33954-bib-0022){ref-type="ref"}, [23](#jah33954-bib-0023){ref-type="ref"}, [24](#jah33954-bib-0024){ref-type="ref"} This may be because of limited cohort sizes in studies and resulting difficulties in getting statistically significant results for subgroups. In recent randomized controlled trials comparing TAVR and SAVR multiple subgroup analyses were performed, but received wide confidence intervals and therefore many results did not achieve statistical significance.[3](#jah33954-bib-0003){ref-type="ref"}, [25](#jah33954-bib-0025){ref-type="ref"} A recently published propensity matched analysis including 9000 patients undergoing SAVR or transapical and transfemoral TAVR in the United States did not find significant differences in 1‐year mortality even in distinct subgroups.[26](#jah33954-bib-0026){ref-type="ref"} Therefore, we performed risk‐adjusted analyses in different subgroups of a large real‐world cohort.[14](#jah33954-bib-0014){ref-type="ref"} Subgroups in the present retrospective study were pre‐defined by typical risk factors for in‐hospital complications such as age, EuroSCORE, sex category, advanced heart failure, peripheral vascular disease, COPD, previous CABG, pulmonary hypertension, renal failure, and diabetes mellitus.[27](#jah33954-bib-0027){ref-type="ref"}, [28](#jah33954-bib-0028){ref-type="ref"}, [29](#jah33954-bib-0029){ref-type="ref"}, [30](#jah33954-bib-0030){ref-type="ref"} Within those subgroups, we found mixed results on in‐hospital outcomes. Risk of stroke was similar apart from patients with previous CABG undergoing TF‐TAVR. They had a reduced risk for stroke after risk adjustment. This is in line with previous studies, which identified previous CABG as a risk factor for stroke after SAVR.[29](#jah33954-bib-0029){ref-type="ref"}, [31](#jah33954-bib-0031){ref-type="ref"} According to randomized controlled trials, acute kidney injuries and relevant bleeding occurred more frequently in patients undergoing SAVR after risk adjustment.[24](#jah33954-bib-0024){ref-type="ref"} Prolonged ventilation was less frequently necessary in patients undergoing TAVR, indicating that TF‐TAVR develops towards a minimalist approach in all analyzed subgroups.[32](#jah33954-bib-0032){ref-type="ref"} Consequently, length of hospital stay was shorter after TF‐TAVR after risk adjustment.

In contrast to the comparison of all patients undergoing SAVR or TF‐TAVR, in‐hospital mortality did differ within particular subgroups. The risk of mortality was lower in patients undergoing TF‐TAVR and aged \>80 years, and this finding was even more pronounced in patients aged \>85 years. These data confirm, in accordance with other studies, that TF‐TAVR is the superior treatment strategy for octogenarians with severe aortic valve stenosis.[13](#jah33954-bib-0013){ref-type="ref"}, [18](#jah33954-bib-0018){ref-type="ref"}

TAVR was initially developed for patients with aortic valve stenosis at increased operative risk.[33](#jah33954-bib-0033){ref-type="ref"} The present study shows that patients at increased operative risk, defined as a EuroSCORE \>99, had decreased risk for mortality after TF‐TAVR compared with SAVR in a real‐world collective. Since a logistic EuroSCORE of 9 is equivalent to an STS score of 4,[34](#jah33954-bib-0034){ref-type="ref"} our data are in line with propensity‐matched comparison of TF‐TAVR and SAVR in the PARTNER II trial, which found favorable outcomes of balloon‐expandable TF‐TAVR in patients at intermediate risk.[12](#jah33954-bib-0012){ref-type="ref"} In contrast, patients treated with a self‐expandable TF‐TAVR had significantly reduced 2‐year mortality, if the STS score was \<7.[35](#jah33954-bib-0035){ref-type="ref"} Two further subgroups benefit from TF‐TAVR: as considered in the established risk scores for cardiac surgery, patients with severe dyspnea or with advanced renal failure are at increased risk for mortality. Accordingly, in‐hospital mortality of patients in NYHA Class III/IV and advanced renal failure was significantly lower if they underwent TF‐TAVR.

Limitations {#jah33954-sec-0020}
===========

First of all, the chosen comparison (SAVR versus TF‐TAVR) assumes that the transfemoral approach is anatomically feasible. Furthermore, apart from the limitations typically associated with retrospective studies, the analysis has several specific limitations: It is based on administrative data, designed to report diagnoses and procedures, and intended to trigger reimbursement. Hence, while the competing interests of hospitals and sickness funds should ensure a high level of data reliability and quality, coding errors cannot be ruled out with certainty, in particular with codes that do not impact reimbursement (such as previous stroke, new atrioventricular block or left bundle branch block, anticoagulation therapy).

Moreover, the administrative data set lacks relevant clinical information (such as echocardiographic findings or anatomical characteristics), preventing operative risk assessment and a better understanding of the underlying valvular pathomechanism. Therefore, only an approximation of the logistic EuroSCORE, in fact a conservative or 'best‐case scenario' estimate, is applied.

When estimating treatment effects, adjusted differences in in‐hospital outcomes may be interpreted as procedure‐related effects if all decision‐ and outcome‐relevant--parameters are used for risk adjustment. Unfortunately, we cannot guarantee that all parameters of relevance are included in the model. Furthermore, even the decision‐making process within the different centers may differ substantially: most centers might have implemented a transfemoral‐first approach as part of the decision process within the interdisciplinary "Heart Team", and some centers might not even have a "Heart Team". In addition, long‐term follow up data are missing, as DESTATIS provides no longitudinal data or cross‐links with other clinical or administrative data sets. Finally, this analysis relies on data from the German healthcare system and other countries' experiences may differ.

Conclusions {#jah33954-sec-0021}
===========

In this study evaluating clinical practice in Germany, we compare in‐hospital outcomes of surgical (SAVR) and transfemoral transcatheter aortic valve replacement (TF‐TAVR) procedures based on *ICD* and OPS codes to identify subgroups of patients for whom either SAVR or TF‐TAVR would be superior. After risk‐adjustment, data show that TF‐TAVR is associated with a decreased risk for in‐hospital mortality in patients with an age \>80 years, at high operative risk, with advanced renal failure, and in NYHA Class III or IV. Outcomes for SAVR or TF‐TAVR in the remaining subgroups were comparable.
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**Table S1.** Diagnosis and Procedure Codes Used for This Analysis

**Table S2.** Analysis Details, All Patients (N=33 789)

**Table S3.** Analysis Details, Patients \<75 Years of Age (n=11 073)

**Table S4.** Analysis Details, Patients \<80 Years of Age (n=8292)

**Table S5.** Analysis Details, Patients \<85 Years of Age (n=8283)

**Table S6.** Analysis Details, Patients 85+ Years of Age (n=6141).

**Table S7.** Analysis Details, Female Patients (n=16 308)

**Table S8.** Analysis Details, Patients in NYHA Class III or IV (n=13 318)

**Table S9.** Analysis Details, Patients With Previous CABG (n=2143)

**Table S10.** Analysis Details, Patients With Atherosclerotic Disease (n=2433)

**Table S11.** Analysis Details, Patients With COPD (n=3900)

**Table S12.** Analysis Details, Patients With Pulmonary Hypertension (n=5616)

**Table S13.** Analysis Details, Patients With GFR \<30 mL (n=1647)

**Table S14.** Analysis Details, Patients With Diabetes Mellitus (n=10 046)

**Table S15.** Analysis Details, Patients With EuroSCORE \<4 (n=7053)

**Table S16.** Analysis Details, Patients With EuroSCORE 4 to 9 (n=12 314)

**Table S17.** Analysis Details, Patients With EuroSCORE \>9 (n=14 402)

**Figure S1.** Results on different subgroups, outcomes, and adjustment strategies.

**Figure S2.** Subgroup‐specific treatment effects regarding length of hospital stay. Results of multivariate logistic regression analyses with 20 predefined baseline patient characteristics included as potential confounders (all covariates listed in Table 1). CABG ‐ coronary artery bypass graft; COPD ‐ chronic obstructive pulmonary disease; EuroSCORE ‐ European System for Cardiac Operative Risk Evaluation; GFR‐ glomerual filtration rate; NYHA ‐ New York Heart Association..
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